Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Daiichi Sankyo
Colorcon
McKinsey
Cipla
Teva
Queensland Health
Boehringer Ingelheim
Deloitte

Generated: December 12, 2018

DrugPatentWatch Database Preview

DIACOMIT Drug Profile

« Back to Dashboard

When do Diacomit patents expire, and when can generic versions of Diacomit launch?

Diacomit is a drug marketed by Biocodex Sa and is included in two NDAs.

The generic ingredient in DIACOMIT is stiripentol. One supplier is listed for this compound. Additional details are available on the stiripentol profile page.

Drug patent expirations by year for DIACOMIT
Generic Entry Opportunity Date for DIACOMIT
Generic Entry Dates for DIACOMIT*:
Constraining patent/regulatory exclusivity:
INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER TAKING CLOBAZAM
NDA:
Dosage:
CAPSULE;ORAL
Generic Entry Dates for DIACOMIT*:
Constraining patent/regulatory exclusivity:
INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER TAKING CLOBAZAM
NDA:
Dosage:
FOR SUSPENSION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for DIACOMIT
(1E)-1-(2H-1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ol
(E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-pent-1-en-3-ol
(E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ol
(E)-1-(3,4-Methylenedioxyphenyl)-4,4-dimethyl-1-penten-3-ol
(E)-1-(Benzo[d][1,3]dioxol-5-yl)-4,4-dimethylpent-1-en-3-ol
1-(1,3-benzodioxol-5-yl)-4,4- dimethyl-1-penten-3-ol
1-(1,3-Benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol
1-(1,3-Benzodioxol-5yl)-4,4-dimethyl-1-penten-3-ol
1-(Benzo[d][1,3]dioxol-5-yl)-4,4-dimethylpent-1-en-3-ol
1-Penten-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-
1-Penten-3-ol, 4,4-dimethyl-1-(3,4-methylenedioxyphenyl)-
137767-55-6
4,4-Dimethyl-1-((3,4-methylenedioxy)phenyl)-1-penten-3-ol
4,4-Dimethyl-1-(3,4-methylenedioxyphenyl)-1-penten-3-ol
4,4-Dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten-3-ol
4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol
49763-96-4
5-19-02-00640 (Beilstein Handbook Reference)
763S964
8269AH
AC1NSKO6
AKOS025149123
AKOS027255159
AN-41512
BCP10434
BCX 2600
BCX-2600
BCX2600
BRN 1313047
C14H18O3
CAS-49763-96-4
CCG-101092
CHEBI:94435
CHEMBL1983350
CPD000449279
CS-7801
D-306
D02XSA
D05928
DB09118
DSSTox_CID_28994
DSSTox_GSID_49068
DSSTox_RID_83259
DTXSID6049068
EBD2763
EINECS 256-480-9
Estiripentol
Estiripentol [INN-Spanish]
GTPL5469
HMS2052K07
HMS2232P06
HY-103392
IBLNKMRFIPWSOY-FNORWQNLSA-N
LS-102117
ME-2080
MFCD00869310
MLS000758313
MLS001424144
MolPort-005-942-442
NC00342
NCGC00185769-01
SAM001247042
SC-53649
SCHEMBL216436
SCHEMBL2533815
SMR000449279
STIRIPENTOL
Stiripentol (JAN/USAN/INN)
Stiripentol (oral)
Stiripentol (oral), Laboratoires Biocodex
Stiripentol [USAN:INN]
Stiripentol, >=98% (HPLC)
Stiripentolum
Stiripentolum [INN-Latin]
Tox21_113622

US Patents and Regulatory Information for DIACOMIT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biocodex Sa DIACOMIT stiripentol CAPSULE;ORAL 206709-001 Aug 20, 2018 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Biocodex Sa DIACOMIT stiripentol FOR SUSPENSION;ORAL 207223-002 Aug 20, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Biocodex Sa DIACOMIT stiripentol CAPSULE;ORAL 206709-002 Aug 20, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Biocodex Sa DIACOMIT stiripentol FOR SUSPENSION;ORAL 207223-002 Aug 20, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Biocodex Sa DIACOMIT stiripentol CAPSULE;ORAL 206709-001 Aug 20, 2018 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Biocodex Sa DIACOMIT stiripentol CAPSULE;ORAL 206709-002 Aug 20, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Biocodex Sa DIACOMIT stiripentol FOR SUSPENSION;ORAL 207223-001 Aug 20, 2018 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Citi
Harvard Business School
Cerilliant
AstraZeneca
Dow
Medtronic
Julphar
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.